Aegerion Pharmaceuticals Announces Final Lomitapide (AEGR-733) Phase II Data
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company focused on the treatment of cardiovascular and metabolic disease, announced final data from three separate Phase II trials involving its lead cholesterol management compound, lomitapide (AEGR-733), which is a microsomal triglyceride transfer protein inhibitor (MTP-I) small molecule drug.
More: continued here
Filed under: Cholesterol on June 20th, 2009
You must be logged in to post a comment.